Dr John Kevin Hart, DPM | |
209 S White St, Mt Pleasant, IA 52641-2157 | |
(319) 385-1128 | |
(319) 385-1129 |
Full Name | Dr John Kevin Hart |
---|---|
Gender | Male |
Speciality | Podiatry |
Experience | 34 Years |
Location | 209 S White St, Mt Pleasant, Iowa |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1174503619 | NPI | - | NPPES |
41870 | Other | IA | BLUE CROSS |
2101345 | Medicaid | IA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
213E00000X | Podiatrist | 00535 (Iowa) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Great River Medical Center | West burlington, IA | Hospital |
Mailing Address | Practice Location Address |
---|---|
Dr John Kevin Hart, DPM Po Box 497, Mt Pleasant, IA 52641-0497 Ph: (319) 385-1128 | Dr John Kevin Hart, DPM 209 S White St, Mt Pleasant, IA 52641-2157 Ph: (319) 385-1128 |
News Archive
Revance Therapeutics, Inc. today announced that the results of two Phase 2b clinical trials on RT001, a topical botulinum toxin type A which is under investigation for the treatment of lateral canthal lines (crow's feet wrinkles) were presented at the annual meeting of the American Society of Dermatologic Surgery in Chicago.
Forget what you know about how diseases are diagnosed-new research published in the May 2010 print issue of The FASEB Journal details a noninvasive ground-breaking tool that detects signs of disease at early molecular stages before symptoms can be seen using traditional methods.
Just a few years ago, so-called pharmacy benefit managers, or PBMs, like Medco would contract with most leading drugstore chains so people could fill their prescriptions almost anywhere they pleased. Then the PBMs realized they could operate more efficiently and profitably by limiting people's choices to a single drugstore -; their own. So they laid down the law with consumers.
ChemGenex Pharmaceuticals Limited announced today that the U.S. Food & Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for Omapro™ (omacetaxine mepesuccinate) for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.
Chimeron Bio, an RNA therapeutics company, and George Mason University's National Center for Biodefense and Infectious Diseases, a leading institute conducting pioneering research on infectious diseases.
› Verified 1 days ago
Seymour Foot & Ankle Center, Pc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 501 S White St, Suite 27, Mt Pleasant, IA 52641 Phone: 319-385-6756 Fax: 319-385-6759 | |
Dr. Michelle R Gerdes-boelens, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 501 S White St, Suite 27, Mt Pleasant, IA 52641 Phone: 319-385-6756 Fax: 319-385-6759 |